Va per altro ricordato che con il [[Vaccino MPR|vaccino contro morbillo-parotite-rosolia]], somministrato nel secondo anno di vita, si è osservato un aumentato del rischio di [[porpora]] da trombocitopenia immunitaria.<ref name="pmid18310189">{{cite journal | vauthors = France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, Marcy M, Mullooly JP, Jackson LA, Nordin J, Belongia EA, Hohman K, Chen RT, Davis R | title = Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children | journal = Pediatrics | volume = 121 | issue = 3 | pages = e687–92 | date = March 2008 | pmid = 18310189 | doi = 10.1542/peds.2007-1578 | url = | issn = }}</ref>
Il vaccino quadrivalente contro il [[papillomavirus umano]] (HPV) ha indotto un caso di trombocitopenia immunitaria secondaria (ITP).,<ref name="Bizjak Bruck Kanduc Praprotnik 2016 pp. S48–S50">{{cite journal | last=Bizjak | first=Mojca | last2=Bruck | first2=Or | last3=Kanduc | first3=Darja | last4=Praprotnik | first4=Sonja | last5=Shoenfeld | first5=Yehuda | title=Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine | journal=Seminars in hematology | publisher=Elsevier BV | volume=53 | year=2016 | issn=0037-1963 | pmid=27312165 | doi=10.1053/j.seminhematol.2016.04.014 | pages=S48–S50}}</ref> insieme a casi di eventi avversi autoimmuni gravi (SAAE).<ref name="Geier Geier 2015 pp. 1225–1231">{{cite journal | last=Geier | first=David A. | last2=Geier | first2=Mark R. | title=A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events | journal=Clinical rheumatology | publisher=Springer Science and Business Media LLC | volume=34 | issue=7 | date=2014-12-23 | year=2015 | issn=0770-3198 | pmid=25535199 | pmc=4475239 | doi=10.1007/s10067-014-2846-1 | pages=1225–1231}}</ref>
